- Palatine’s initial investment in Veincentre was in July 2019
- Veincentre had an increase in revenue of over 180% over the course of the investment
- The exit is the second from Palatine’s Impact Fund
Palatine announced on Monday that it had sold its stake in Veincentre to CBPE Capital. Veincentre is the UK’s largest chain of varicose vein treatment clinics, according to Palatine. The sale is the second from Palatine’s Impact Fund following its exit from Estio Training in November 2021.
Following Palatine’s investment in Veincentre in July 2019, the company expanded its footprint of clinics from seven to 22 across the UK. The Stoke-on-Trent-headquartered company had an increase in enquiries by 270 percent and an increase in revenue of over 180 percent over the course of the investment.
“Having supported significant growth in the leadership team and established and expanded the digital marketing function, Veincentre is very well-placed to continue its growth journey,” said James Painter, investment director at Palatine.
Palatine is a Manchester-headquartered private equity and venture capital firm. It has two funds, Buyout and Impact, and was founded in 2005.
The buyer, CBPE, invests in UK mid-market businesses with an enterprise value of up to £150 million. It was founded in 1984 and is headquartered in London.